Warning: Kayexalate, Sodium Polystyrene Sulfonate

The FDA has published a safety communication on potassium-lowering drug Kayexalate and other brands of sodium polystyrene sulfonate because it has been found to bind to other oral medications, reducing their effectiveness.  The FDA recommends separating the dosing of sodium polystyrene sulfonate from other orally administered medicines by at least 3 hours.  They are updating sodium polystyrene sulfonate drug labels to include information about this dosing separation.  For details see https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm574763.htm .

Recalls: Baxter PD Systems

Because of instruction-manual issues which may lead to cassette damage that could result in the delivery of air into patients, the FDA has announced Class II recalls of: